Clinical trials are research studies designed to find better ways to treat patients with cancer and other diseases. Treatments – usually in the form of drugs, a new way of using existing treatment or newly developed treatment methods – are developed and tested for years in the lab before they are tested in people. Once the new treatment shows promise for being better than the standard current treatment, it must be tested through a clinical trial before it is approved by the FDA.
The potential for participating in a clinical trial is one of the many benefits of seeking care at an NCI-designated Comprehensive Cancer Center such as the University of Maryland Greenebaum Comprehensive Cancer Center. Clinical trials offer patients access to advanced treatments years before they may be widely available.
Current Bone Cancer and Soft Tissue Sarcoma Clinical Trials at UMGCCC
Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Trial
Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multi-agent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, or Non-Small Cell Lung Cancer, and Other B7-H3-Expressing Cancers